US Patent No: 7,846,725

Number of patents in Portfolio can not be more than 2000

Antibody composition-producing cell in which enzyme expression is inhibited by RNAi

ALSO PUBLISHED AS: 20080261301

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, wherein the expression of GDP-mannose 4,6-dehydrogenase is inhibited by RNA interference.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
KYOWA HAKKO KIRIN CO., LTD.TOKYO301

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hanai, Nobuo Machida, JP 134 1175
Hosaka, Emi Machida, JP 74 723
Kanda, Yutaka Machida, JP 117 955
Nakamura, Kazuyasu Machida, JP 129 979
Satoh, Mitsuo Machida, JP 70 664
Shinkawa, Toyohide Machida, JP 59 748
Uchida, Kazuhisa Machida, JP 68 814
Yamane, Naoko Machida, JP 58 727
Yamano, Kazuya Machida, JP 55 462
Yamasaki, Motoo Machida, JP 122 990

Cited Art Landscape

Patent Info (Count) # Cites Year
 
KYOWA HAKKO KIRIN CO., LTD. (36)
5,830,470 Humanized antibodies to ganglioside GM.sub.2 44 1993
6,018,032 Antibody against human interleukin-5-receptor .alpha. chain 33 1997
6,437,098 Human chimeric antibody specific for the ganglioside GD3 24 1999
6,986,890 Anti-human VEGF receptor Flt-1 monoclonal antibody 29 1999
6,989,145 Recombinant antibody and antibody fragment 33 2001
6,946,292 Cells producing antibody compositions with increased antibody dependent cytotoxic activity 82 2001
2003/0175,273 Human CDR-grafted antibody and antibody fragment thereof 25 2002
7,691,568 Antibody composition-containing medicament 9 2003
2004/0110,282 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost 40 2003
2004/0132,140 Production process for antibody composition 47 2003
7,691,810 Method of producing recombinant antithrombin III composition 9 2004
2005/0187,380 Method for treating Th2-mediated disease 21 2005
7,214,775 Method of modulating the activity of functional immune molecules 63 2005
7,708,992 Methods for producing antibody compositions with increased ADCC 11 2005
2005/0272,916 Method of modulating the activity of functional immune molecules 33 2005
2006/0024,800 Method of modulating the activity of functional immune molecules 28 2005
2005/0216,958 Cells of which genome is modified 24 2005
2005/0262,593 Antibody composition-producing cell 27 2005
2006/0223,147 Process for producing glycoprotein composition 24 2005
2006/0063,254 Antibody composition-producing cell 32 2005
2006/0064,781 Antibody composition-producing cell 34 2005
7,393,683 Mammalian host cell modified by RNAi to inhibit .alpha. 1,6-fucosyltransferase 15 2005
7,425,446 Antibody composition-producing cell 16 2005
7,709,234 α-1,3-fucosyltransferase 10 2006
2007/0148,165 Recombinant antibody composition 17 2006
7,651,688 Method of modulating the activity of functional immune molecules to CD52 10 2007
7,655,228 Method of modulating the activity of functional immune molecules to GM2 10 2007
7,682,610 Method of modulating the activity of functional immune molecules 10 2007
7,682,611 Method of modulating the activity of functional immune molecules to CXCR4 protein 10 2007
7,708,997 Method of modulating the activity of functional immune molecules 10 2007
2007/0166,300 Method of Modulating the Activity of Functional Immune Molecules 23 2007
2007/0166,301 Method of Modulating the Activity of Functional Immune Molecules 23 2007
2007/0166,302 Method of Modulating the Activity of Functional Immune Molecules 23 2007
2007/0166,303 Method of Modulating the Activity of Functional Immune Molecules 23 2007
2007/0166,304 Method of Modulating the Activity of Functional Immune Molecules 23 2007
2008/0261,301 Antibody Composition-Producing Cell 21 2008
 
KYOWA HAKKO KOGYO CO., LTD. (5)
2004/0093,621 Antibody composition which specifically binds to CD20 74 2002
2004/0110,704 Cells of which genome is modified 51 2003
2005/0160,485 Mouse in which genome is modified 21 2004
2005/0226,867 IL-5R-specific antibody composition 22 2004
2005/0287,138 CCR4-specific antibody composition 23 2004
 
ROCHE GLYCART AG (5)
6,602,684 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 109 1999
2004/0072,290 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 54 2003
2005/0074,843 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 39 2003
2005/0079,605 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 35 2003
2007/0111,281 Antigen binding molecules having modified Fc regions and altered binding to Fc receptors 32 2006
 
Genentech, Inc. (4)
4,816,567 Recombinant immunoglobin preparations 1622 1983
6,169,070 Mer receptor activation by gas6 69 1996
6,737,056 Polypeptide variants with altered effector function 213 2000
7,297,775 Polypeptide variants 35 2002
 
ICOS CORPORATION (3)
5,880,268 Modulators of the interaction between ICAM-R and .alpha..sub.d /CD18 29 1995
5,932,703 Macrophage derived chemokine and chemokine analogs 35 1996
6,498,015 Methods of identifying agents that modulate the binding between MDC and an MDC receptor 30 1997
 
MILLENNIUM PHARMACEUTICALS, INC. (2)
6,488,930 Anti-CCR4 antibodies and methods of use therefor 31 1999
7,138,117 Anti-CCR4 antibodies and methods of use therefor 22 2002
 
PANASONIC CORPORATION OF NORTH AMERICA (2)
7,687,061 Method of modulating the activity of functional immune molecules to Her-2 10 2007
2007/0166,305 Method of Modulating the Activity of Functional Immune Molecules 23 2007
 
TANIGUCHI, NAOYUKI (2)
6,054,304 .alpha.1-6 fucosyltransferase 44 1998
6,291,219 .alpha.1-6 fucosyltransferase 21 1999
 
TOUDAI TLO, LTD. (2)
2004/0002,077 siRNA expression system and method for producing functional gene knock-down cell using the system 61 2002
2005/0048,647 Sirna expression system and process for producing functional gene knockdown cell or the like using the same 44 2004
 
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2)
5,977,316 Monoclonal antibody 1A7 and related polypeptides 29 1996
5,935,821 Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma 43 1996
 
ACTIVCARD IRELAND LIMITED (1)
7,502,497 Method and system for extracting an area of interest from within an image of a biological surface 19 2007
 
BIOGEN IDEC MA INC. (1)
7,033,589 γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics 23 1999
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5,272,070 Method for the preparation of cell lines producing Man.sub.3 GlcN.sub.ac 2 asparagine-linked gylcans and cell lines produced thereby 58 1991
 
Boehringer Mannheim GmbH (1)
5,453,363 Process for the activation of t-PA or Ing after genetic expression in prokaryotes 34 1994
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
4,350,683 Antibody production from hybrid cell line 71 1980
 
CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY (1)
6,540,980 Method of detecting endometriosis 24 2000
 
CENTRO DE INMUNOLOGIA MOLECULAR (1)
5,891,996 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use 86 1995
 
CHUGAI SEIYAKU KABUSHIKI KAISHA (1)
2003/0190,316 Stabilized antibody-containing preparations 57 2003
 
Desmos, Inc. (1)
5,658,789 Promotion of epithelial cell adhesion and hemidesmosome assembly by a laminin-like molecule 27 1995
 
DOVETAIL TECHNOLOGIES INC. (1)
6,762,174 Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof 20 1999
 
FUJITSU LIMITED (1)
6,189,781 Terminal unit having function for converting commodity information into bar code and vice versa 31 1994
 
GENENEWS INC. (1)
2005/0208,519 Biomarkers for diagnosing schizophrenia and bipolar disorder 11 2004
 
GENETICS INSTITUTE, LLC (1)
5,728,568 Human GDP-mannose 4,6 dehydratase 29 1996
 
GLAXO GROUP LIMITED (1)
6,150,132 Chemokine receptor able to bind to MCP-1, MIP-1.alpha. and/or RANTES. Its uses 40 1997
 
GLAXOSMITHKLINE LLC (1)
5,783,184 Method for treatment and diagnosis of IL-5 mediated disorders 14 1996
 
Hazleton Biotechnologies, Inc. (1)
4,757,018 Myeloma cell lines and uses thereof 27 1985
 
IDEC PHARMACEUTICALS CORPORATION (1)
6,455,043 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody 62 1999
 
LEUKOSITE, INC. (1)
6,245,332 Modulation of systemic memory T cell trafficking 30 1999
 
LONZA GROUP AG (1)
5,672,502 Animal cell culture 32 1995
 
MARIEL THERAPEUTICS, INC. (1)
5,614,385 Methods and compositions for high protein production from recombinant DNA 29 1995
 
MEDAREX, INC. (1)
5,922,845 Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies 81 1996
 
OSAKA UNIVERSITY (1)
2003/0170,813 Process for producing glycoprotein 22 2003
 
SMITHKLINE BEECHAM P.L.C. (1)
6,129,913 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders 25 1997
 
SRD PHARMACEUTICALS, INC. (1)
5,665,569 HIV immunotherapeutics 35 1994
 
TAKATSU, KIYOSHI (1)
5,916,767 DNA encoding human interleukin-5 receptor 11 1997
 
THE GENERAL HOSPITAL CORPORATION (1)
5,858,983 Inhibition of cell adhesion protein-carbohydrate interactions 39 1995
 
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (1)
6,238,894 .alpha.1,2 fucosyltransferase 25 1999
 
The Green Cross Corporation (1)
4,721,777 Process for the virus-inactivation of immunoglobulin 36 1985
 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (1)
6,350,868 Antisense human fucosyltransferase sequences and methods of use thereof 23 2000
 
THERMO FISHER SCIENTIFIC INC. (1)
2007/0031,844 Functional and hyperfunctional siRNA 309 2003
 
UNIVERSITY OF UTAH (1)
5,464,764 Positive-negative selection methods and vectors 223 1993
 
WISTAR INSTITUTE, THE, A CORP. OF PA (1)
4,849,509 Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies 49 1987

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
KYOWA HAKKO KIRIN CO., LTD. (8)
8,067,232 Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase 0 2008
8,158,760 Glycoengineered, recombinant antibody 0 2009
8,039,595 Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation 2 2009
8,367,407 Cells with altered fucosylation and producing antibodies therefrom 0 2009
8,679,491 Method of modulating the activity of functional immune molecules 0 2009
8,110,195 Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody 0 2010
8,101,185 Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation 0 2010
8,329,443 Antibody composition-producing cell 0 2011
 
BIOWA, INC. (1)
8,501,176 Methods of reducing eosinophil levels 0 2011

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 7, 2014
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 7, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 7, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00